Dear Dr. Chan:

Please refer to your Supplemental New Drug Application (sNDA) dated December 22, 2011, submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tekurna (aliskiren) 150 mg, 300 mg tablets.

We also refer to our approval letter dated February 2, 2012 which contained the following error: the incorrect labeling was attached.

This replacement approval letter incorporates the correction of the error. The effective approval date will remain February 2, 2012, the date of the original approval letter.

This “Prior Approval” supplemental new drug application provides for labeling revised as follows:

1. In **HIGHLIGHTS** and **Full Prescribing Information**, the boxed warning was changed:

   **WARNING: FETAL TOXICITY**
   - When pregnancy is detected, discontinue Tekturna as soon as possible (5.1)
   - Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (5.1)

2. Under **WARNINGS AND PRECAUTIONS**, the section was changed from:

   **5.1 Fetal/Neonatal Morbidity and Mortality**

   Drugs that act directly on the renin-angiotensin system can cause fetal and neonatal morbidity and death when administered to pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to the fetus [see Use in Specific
Populations (8.1)]. In several dozen published cases, ACE inhibitors use during the second and third trimesters of pregnancy was associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. In addition, first trimester use of ACE inhibitors has been associated with birth defects in retrospective data.

To:

5.1 Fetal toxicity
Pregnancy Category D

Use of drugs that act on the renin-angiotensin system during the second and third trimesters reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Tekturna as soon as possible. [see Use in Specific Populations (8.1)]

3. Under USE IN SPECIFIC POPULATIONS, the section was changed from:

8.1 Pregnancy
Pregnancy Categories C (first trimester) and D (second and third trimesters) [See Warnings and Precautions (5.1)]

There is no clinical experience with the use of Tekturna in pregnant women. Drugs that act directly on the renin-angiotensin system can cause fetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been reported in the world literature in patients who were taking angiotensin-converting enzyme inhibitors. When pregnancy is detected, Tekturna should be discontinued as soon as possible. The use of drugs that act directly on the renin-angiotensin system during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal contractures, craniofacial deformation, and hypoplastic lung development. Prematurity, intrauterine growth retardation, and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to exposure to the drug.

In addition, first trimester use of ACE inhibitors, a specific class of drugs acting on the renin-angiotensin system, has been associated with a potential risk of birth defects in retrospective data. Healthcare professionals that prescribe drugs acting directly on the renin-angiotensin system should counsel women of childbearing potential about the potential risks of these agents during pregnancy. Rarely (probably less often than once in every thousand pregnancies), no alternative to a
drug acting on the renin-angiotensin system will be found. In these rare cases, the mothers should be apprised of the potential hazards to their fetuses and serial ultrasound examination should be performed to assess the intra-amniotic environment. If oligohydramnios is observed, Tekturna should be discontinued unless it is considered life-saving for the mother. Contraction stress testing (CST), a nonstress test (NST) or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy. Patients and physicians should be aware; however that oligohydramnios may not appear until after the fetus has sustained irreversible injury.

Infants with histories of in-utero exposure to a renin inhibitor should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as means of reversing hypotension and/or substituting for disordered renal function. [See Nonclinical Toxicology (13)]

8.1 Pregnancy

Pregnancy Category D

Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasiya and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Tekturna as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus.

In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue Tekturna, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to Tekturna for hypotension, oliguria, and hyperkalemia. [see Use in Specific Populations (8.4)]
4. Under **USE IN SPECIFIC POPULATIONS/Pediatric Use**, a new section was added:

   Neonates with a history of in utero exposure to Tekturna:
   If oliguria or hypotension occurs, direct attention toward support of blood
   pressure and renal perfusion. Exchange transfusions or dialysis may be required
   as a means of reversing hypotension and/or substituting for disordered renal
   function.

5. Under **PATIENT COUNSELING INFORMATION**, the section was changed from:

   Female patients of childbearing age should be told about the consequences of
   exposure to drugs that act on the renin-angiotensin system. Discuss other
   treatment options with female patients planning to become pregnant. These
   patients should be asked to report pregnancies to their physicians as soon as
   possible.

   To:

   Female patients of childbearing age should be told about the consequences of
   exposure to Tekturna during pregnancy. Discuss treatment options with women
   planning to become pregnant. Patients should be asked to report pregnancies to
   their physicians as soon as possible.

6. The revision date and version number were updated.

There are no other changes from the last approved package insert.

**The following change was made to the Patient Information Section:**

1. Under **What is the most important information I should know about Tekturna?**, the
   section was changed from:

   IMPORTANT WARNING: If you get pregnant, stop taking Tekturna and
   call your doctor right away. Tekturna may harm an unborn baby, causing
   injury and even death. If you plan to become pregnant, talk to your doctor
   about other treatment options before taking Tekturna.

   To:

   What is the most important information I should know about Tekturna?

   Tekturna can cause harm or death to an unborn baby. Talk to your doctor
   about other ways to lower your blood pressure if you plan to become
   pregnant. If you get pregnant while taking Tekturna, tell your doctor right
   away.
2. Under **Tell your doctor about all your medical conditions, including whether you:**,
the first bullet was changed from:

- are pregnant or planning to become pregnant. See IMPORTANT WARNING

To:

- are pregnant or planning to become pregnant. See What is the most important information I should know about Tekturna?

3. Under Tekturna may cause serious side effects:, the first bullet was changed from:

- **Injury or death to an unborn baby.** See IMPORTANT WARNING

To:

- **Injury or death to an unborn baby.** See What is the most important information I should know about Tekturna?

4. The revision date and version number were updated.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements and any annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.
PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at [http://www.fda.gov/opacom/morechoices/fdaforms/cder.html](http://www.fda.gov/opacom/morechoices/fdaforms/cder.html); instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see [http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm](http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm).

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program  
Office of Special Health Issues  
Food and Drug Administration  
10903 New Hampshire Ave  
Building 32, Mail Stop 5353  
Silver Spring, MD 20993

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, please call

Lori Anne Wachter, RN, BSN
Regulatory Project Manager for Safety
(301) 796-3975

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, PharmD
Deputy Director for Safety
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
   Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY R SOUTHWORTH
02/02/2012